Compare Summit Therapeutics Inc (SMMT) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Invesco Solar ETF — how do they compare? Summit Therapeutics Inc trades at $17.54 (market cap $13.71B), while Invesco Solar ETF trades at $43.67 (market cap $894.08M). The key difference: Summit Therapeutics Inc is far larger — about 15.3× Invesco Solar ETF's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Invesco Solar ETF for 34 Days on average.
| SMMT | TAN | |
|---|---|---|
Market Cap | $13.71B | $894.08M |
Volume | 6,173,057 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $26.38 | $73.95 |
52-Week Low | $12.43 | $43.00 |
Typical Hold Time | 16 Days | 34 Days |
Enterprise Value | $13.04B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
TAN trades at $43.6, up 0.16% on the day, amid a bearish technical signal with moving averages and key indicators like ADX signaling sell conditions. The ETF faces headwinds from high borrowing costs impacting solar project financing, as noted in recent news. Financial ratios are unavailable, but the fund's high expense ratio of 0.7% and historical volatility are points of concern for investors.
Outlook remains cautious due to sector-specific risks like interest rate sensitivity and market saturation. Investment opportunities exist for those bullish on long-term solar adoption, but risks include policy uncertainty and cost pressures. Analyst sentiment is mixed, with some highlighting underperformance versus broader markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
